Factor IXa specific antibodies displaying factor VIIIa like activity
View Patent ↗Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating patients afflicted with blood coagulation with such ligands, and a nucleic acid that encodes, or a cell that expresses such ligands, are provided.
1. An isolated antibody comprising
a V H domain having a CDR1 comprising the sequence set forth in SEQ ID NO:6, a CDR2 comprising the sequence set forth in SEQ ID NO:7, and a CDR3 comprising the sequence set forth in SEQ ID NO:8; and
a V L domain having a CDR1 comprising the sequence set forth in SEQ ID NO:3, a CDR2 comprising the sequence set forth in SEQ ID NO:4, and a CDR3 comprising the sequence set forth in SEQ ID NO:5,
wherein the antibody can bind to Factor IX/Factor IXa and increase the procoagulation activity of Factor IXa.
2. The isolated antibody according to claim 1 , wherein the V H domain comprises the sequence set forth in SEQ ID NO:1 and
the V L domain comprises the sequence set forth in SEQ ID NO:2.
3. The isolated antibody according to claim 1 , wherein the antibody is an IgG.
4. The isolated antibody according to claim 1 , wherein the antibody is monoclonal.
5. The isolated antibody according to claim 1 , wherein the antibody is an antibody fragment.
6. The isolated antibody according to claim 1 , wherein the antibody is a recombinant antibody.
7. The isolated antibody according to claim 6 , wherein the antibody is a single chain antibody.
8. The isolated antibody according to claim 1 , wherein the antibody is a humanized antibody.
9. The isolated antibody of claim 1 , wherein the antibody is labeled.
10. A pharmaceutical composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier and/or diluent.
11. The pharmaceutical composition comprising the isolated antibody of claim 2 .
12. The pharmaceutical composition according to claim 11 , further comprising a Factor selected from the group consisting of Factor IX, Factor IXaα, Factor IXaβ, and combinations thereof.
13. The pharmaceutical composition according to claim 10 , further comprising a Factor selected from the group consisting of Factor IX, Factor IXaα, Factor IXaβ, and combinations thereof.